<link rel='stylesheet' href='https//fonts.googleapis.com/css?family=Roboto:400,500,700,400italic|Material+Icons'>
Open Search
VRDN
Viridian Therapeutics
$
()


  • Viridian Therapeutics price target lowered by $4 at B. Riley, here's why

    3/21/2024 - 08:46am
  • Viridian Therapeutics price target lowered by $2 at Wells Fargo, here's why

    2/29/2024 - 06:16am
  • Viridian Therapeutics price target raised by $1 at Wedbush, here's why

    2/28/2024 - 08:49am
  • Viridian Therapeutics price target lowered by $1 at JMP Securities, here's why

    2/28/2024 - 06:44am
  • Viridian Therapeutics expects cash to fund operations into second half of 2026

    2/27/2024 - 16:08pm
  • Viridian Therapeutics reports Q4 EPS ($1.35), consensus ($1.00)

    2/27/2024 - 16:07pm
  • Viridian Therapeutics names Jennifer Tousignant chief legal officer

    2/16/2024 - 08:06am
  • Viridian Therapeutics price target lowered by $1 at Wedbush, here's why

    1/22/2024 - 08:31am
  • Viridian Therapeutics 7.14M share Spot Secondary priced at $21.00

    1/17/2024 - 22:45pm
  • Viridian announces offering of common stock, Series B preferred stock

    1/17/2024 - 16:05pm
  • Spyre Therapeutics price target raised by $9 at Stifel, here's why

    1/12/2024 - 07:36am
  • Apogee Therapeutics price target raised by $12 at Stifel, here's why

    1/12/2024 - 07:35am
  • Short Report: Bears boost exposure to Rocket Companies despite dovish Fed tilt

    12/22/2023 - 13:16pm
  • Viridian Therapeutics price target raised to $36 from $35 at Oppenheimer

    12/19/2023 - 07:27am
  • Viridian selectsVRDN- 003 as lead SC program for TED

    12/18/2023 - 07:10am
dynamic_feed Breaking News